MedTrace Logo

A Comparison Study of PF708 and Forteo in Healthy Subjects

NCT02656810 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 70

Last updated 2016-08-04

No results posted yet for this study

Summary

The purpose of this study is to compare the pharmacokinetics (blood levels) of two teriparatide products, PF708 and Forteo, in healthy subjects.

Conditions

Interventions

DRUG

Teriparatide

Single subcutaneous injection

Sponsors & Collaborators

  • Pfenex, Inc

    lead INDUSTRY

Principal Investigators

  • Hubert C Chen, M.D. · Pfenex, Inc

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
50 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2015-12-31
Primary Completion
2016-07-31
Completion
2016-07-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02656810 on ClinicalTrials.gov